R. Bissonnette

发表

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle‐controlled study

H. Hofland, R. Bissonnette, Y. Poulin, 2017, Journal of the American Academy of Dermatology.

Psoriatic plaques exhibit red autofluorescence that is due to protoporphyrin IX.

H. Lui, D. McLean, H. Zeng, 1998, The Journal of investigative dermatology.

Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel

K. Papp, R. Bissonnette, Y. Poulin, 2004, Journal of cutaneous medicine and surgery.

GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis.

G. Gudi, Ning Zhang, G. Wolff, 2019, The Journal of allergy and clinical immunology.

Chapter 11 Systemic sensitization — non-oncologic indications in dermatology

H. Lui, R. Bissonnette, 2001 .

Apoptosis and cancer.

D. Green, T. Cotter, R. Bissonnette, 1994, Important advances in oncology.

The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.

S. Feldman, J. Silverberg, T. Bieber, 2020, Journal of the American Academy of Dermatology.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis

M. Gooderham, K. Papp, R. Bissonnette, 2018, Journal of cutaneous medicine and surgery.

Efficacy and safety of topical WBI‐1001 in patients with mild to severe atopic dermatitis: results from a 12‐week, multicentre, randomized, placebo‐controlled double‐blind trial

R. Bissonnette, Y. Poulin, Y. Zhou, 2012, The British journal of dermatology.

Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial.

Youwen Zhou, R. Bissonnette, C. Maari, 2010, Archives of dermatology.

Open-Label Study to Assess the Safety and Efficacy of Imiquimod 5% Cream Applied Once Daily Three Times per Week in Cycles for Treatment of Actinic Keratoses on the Head

R. Bissonnette, J. Rivers, N. Provost, 2008, Journal of cutaneous medicine and surgery.

Topical photodynamic therapy with 5‐aminolaevulinic acid does not induce hair regrowth in patients with extensive alopecia areata

H. Lui, J. Shapiro, D. McLean, 2000, The British journal of dermatology.

Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate‐photodynamic therapy

J. Lear, N. Basset-Seguin, R. Bissonnette, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial.

Anders B. Dohlman, Avi Ma’ayan, R. Gregg, 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy Phase 3 trial in the United States and Canada (BREEZE-AD5).

J. Silverberg, K. Papp, E. Simpson, 2021, Journal of the American Academy of Dermatology.

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

J. Silverberg, T. Bieber, A. Paller, 2020, The British journal of dermatology.

Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials

T. Bieber, J. Thyssen, M. Gooderham, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation

S. Ziegler, R. Geha, A. McKenzie, 2020, The Journal of allergy and clinical immunology.

Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial.

J. Werth, R. Bissonnette, C. Zang, 2019, The Journal of allergy and clinical immunology.

Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis

J. Silverberg, G. Yancopoulos, A. Menter, 2019, The Journal of allergy and clinical immunology.

The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition

M. Boguniewicz, A. Wollenberg, R. Bissonnette, 2018, Experimental dermatology.

Safety profile of intravenous and subcutaneous siplizumab, an anti‐CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double‐blind, placebo‐controlled studies

K. Papp, R. Bissonnette, R. Langley, 2010, International journal of dermatology.

Update on Alefacept Safety

W. Gulliver, K. Papp, R. Bissonnette, 2009, Journal of cutaneous medicine and surgery.

Efficacy Outcomes in Patients Using Alefacept in the AWARE Study

H. Lui, R. Bissonnette, N. Shear, 2009, Journal of cutaneous medicine and surgery.

Clinical Experience with Alefacept in Canadian Patients with Psoriasis: The Amevive Wisdom Acquired from Real-world Evidence (AWARE) Study

R. Bissonnette, N. Shear, G. Searles, 2009 .

Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab

K. Papp, R. Bissonnette, R. Langley, 2009, Archives of Dermatological Research.

XP-828 L in the Treatment of Mild-to-Moderate Psoriasis : A Randomized , Double-blind , Placebo-controlled Study

R. Bissonnette, Y. Poulin, P. Poubelle, 2007 .

XP-828L in the Treatment of Mild to Moderate Psoriasis: Randomized, Double-Blind, Placebo-Controlled Study

R. Bissonnette, Y. Poulin, P. Poubelle, 2006, Journal of cutaneous medicine and surgery.

Irradiance and light dose influence histological localization of photodamage induced by photodynamic therapy with aminolaevulinic acid

R. Bissonnette, S. Sharfaei, G. Viau, 2004, The British journal of dermatology.

Topical Vitamin E Cream Does Not Prevent Visible Light-Induced Pigmentation

R. Bissonnette, C. Maari, C. Bolduc, 2018, Journal of cutaneous medicine and surgery.

Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial

L. Iversen, H. Valdez, P. Foley, 2015, The British journal of dermatology.

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

K. Papp, R. Bissonnette, L. Rosoph, 2008, The Lancet.

Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review

W. Gulliver, J. Pope, B. Haraoui, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Psoriasis and Smoking

W. Gulliver, J. Pope, B. Haraoui, 2016, Journal of cutaneous medicine and surgery.

Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.

K. Papp, R. Bissonnette, Y. Poulin, 2012, Journal of the American Academy of Dermatology.

Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary

A. Bitton, Deepali Kumar, S. Jamal, 2019, Journal of the Canadian Association of Gastroenterology.

Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary

A. Bitton, Deepali Kumar, S. Jamal, 2019, The Journal of Rheumatology.

Long-Term Safety of Etanercept

E. Keystone, K. Papp, R. Bissonnette, 2007 .

Dr. Roubille, et al reply

W. Gulliver, J. Pope, B. Haraoui, 2016, The Journal of Rheumatology.

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis

John D. Davis, G. Yancopoulos, N. Stahl, 2019, JAMA dermatology.

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

E. Peeva, M. Gooderham, S. Forman, 2019, JAMA dermatology.

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.

J. Silverberg, E. Simpson, K. Reich, 2021, JAMA dermatology.

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.

J. Tardif, M. Guertin, R. Bissonnette, 2017, The Journal of investigative dermatology.

Effects of the Tumor Necrosis Factor-&agr; Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis: Results of a Randomized Controlled Trial

J. Tardif, J. Pressacco, M. Guertin, 2013, Circulation. Cardiovascular imaging.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

K. Reich, K. Gordon, Y. Wasfi, 2015, The New England journal of medicine.

Efficacy and safety of topical WBI‐1001 in patients with mild to moderate psoriasis: results from a randomized double‐blind placebo‐controlled, phase II trial

R. Bissonnette, S. Nigen, C. Maari, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Systemic photodynamic therapy with aminolevulinic acid induces apoptosis in lesional T lymphocytes of psoriatic plaques.

H. Lui, P. Juzenas, R. Bissonnette, 2002, The Journal of investigative dermatology.

Oral Aminolevulinic Acid Induces Protoporphyrin IX Fluorescence in Psoriatic Plaques and Peripheral Blood Cells † ¶

M. Korbelik, D. McLean, H. Lui, 2001 .

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).

B. Strober, M. Lebwohl, L. Naldi, 2016, Journal of the American Academy of Dermatology.

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferon-alfa monoclonal antibody, in subjects with chronic psoriasis.

W. White, K. Papp, G. Robbie, 2010, Journal of the American Academy of Dermatology.

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

B. Strober, A. Gottlieb, K. Papp, 2021, Drug Safety.

Efficacy and safety of oral alitretinoin (9‐cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double‐blind, placebo‐controlled, multicentre trial

P. Elsner, Å. Svensson, M. Lahfa, 2008, The British journal of dermatology.

Multiple large surface photodynamic therapy sessions with topical methylaminolaevulinate in PTCH heterozygous mice

R. Bissonnette, G. Viau, Y. Liu, 2005, The British journal of dermatology.

Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumours in mice

J. Moan, P. Juzenas, R. Bissonnette, 2002, Archives of Dermatological Research.

Chemopreventative thoughts for photodynamic therapy.

R. Bissonnette, 2007, Dermatologic clinics.

Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study

A. Menter, E. Edson-Heredia, K. Reich, 2019, The British journal of dermatology.

Persistence of interleukin (IL)‐17A+ T lymphocytes and IL‐17A expression in treatment‐resistant psoriatic plaques despite ustekinumab therapy

R. Bissonnette, M. Sarfati, N. Arbour, 2017, The British journal of dermatology.

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

R. Bissonnette, Y. Frambach, C. Papavassilis, 2015, The British journal of dermatology.

A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris

G. Murphy, A. Chu, R. Bissonnette, 2002, Dermatology.

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

T. Luger, U. Mrowietz, R. Bissonnette, 2017, The British journal of dermatology.

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

T. Luger, U. Mrowietz, R. Bissonnette, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

John D. Davis, I. Hussain, S. Forman, 2020 .

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.

John D. Davis, I. Hussain, M. D. de Bruin‐Weller, 2020, Journal of the American Academy of Dermatology.

A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis

Haifeng Zhang, A. Menter, P. Scherle, 2016, The Journal of dermatological treatment.

Comparison of the Inflammatory Circuits in Psoriasis Vulgaris, Non-Pustular Palmoplantar Psoriasis, and Palmoplantar Pustular Psoriasis.

R. Bissonnette, M. Sleeman, J. Krueger, 2022, The Journal of investigative dermatology.

Meta‐Analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials

W. Gulliver, J. Pope, B. Haraoui, 2015, Arthritis care & research.

Biomarkers in atopic dermatitis - a review on behalf of the international eczema council.

T. Bieber, J. Thyssen, K. Kabashima, 2021, The Journal of allergy and clinical immunology.

Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

C. Flohr, J. Thyssen, A. Drucker, 2022, Dermatitis : contact, atopic, occupational, drug.

Psoriasis: why does it come with a greater risk of heart attack and stroke?

R. Bissonnette, 2012 .

A randomized study comparing the combination of nbUVB and etanercept to etanercept monotherapy in patients with psoriasis who do not exhibit an excellent response after 12 weeks of etanercept

R. Bissonnette, Y. Poulin, L. Guenther, 2012, The Journal of dermatological treatment.

Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials

A. Menter, R. Bissonnette, L. Puig, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.

M. Suárez-Fariñas, R. Bissonnette, J. Krueger, 2016, The Journal of investigative dermatology.

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study

M. Gooderham, J. Fowler, R. Bissonnette, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis

J. Silverberg, A. Paller, J. Thyssen, 2022, British Journal of Dermatology.

The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody.

H. Lui, J. Shapiro, W. Gulliver, 2001, Journal of the American Academy of Dermatology.

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement

J. Silverberg, A. Paller, M. Cork, 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

Molecular signatures order the potency of topically applied anti‐inflammatory drugs in patients with atopic dermatitis

M. Suárez-Fariñas, R. Bissonnette, M. Suprun, 2017, The Journal of allergy and clinical immunology.

Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis.

R. Bissonnette, M. Sarfati, S. Mashiko, 2017, Journal of dermatological science.

Increased expression of IL‐17A and limited involvement of IL‐23 in patients with palmo‐plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial

R. Bissonnette, C. Lynde, R. Langley, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study†

L. Denis, S. Forman, J. Fowler, 2019, The British journal of dermatology.

Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

K. Schäkel, K. Reich, U. Mrowietz, 2021, Dermatology and Therapy.

Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway.

M. Suárez-Fariñas, R. Bissonnette, J. Krueger, 2017, Journal of dermatological science.

Treatment of palmoplantar psoriasis with infliximab: a randomized, double‐blind placebo‐controlled study

R. Bissonnette, Y. Poulin, L. Guenther, 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

Response to Hjuler et al.

J. Tardif, M. Guertin, R. Bissonnette, 2017, The Journal of investigative dermatology.

Risk of Myocardial Infarction in Canadian Patients with Psoriasis: A Retrospective Cohort Study

R. Bissonnette, J. Lachaine, A. Levesque, 2013, Journal of cutaneous medicine and surgery.

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

M. D. de Bruin‐Weller, T. Nakahara, A. Shabbir, 2022, American Journal of Clinical Dermatology.

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

I. Hussain, M. D. de Bruin‐Weller, M. Ardeleanu, 2020, American Journal of Clinical Dermatology.

IL-23/IL-17A Dysfunction Phenotypes Inform Possible Clinical Effects from Anti-IL-17A Therapies

M. Lebwohl, A. Blauvelt, R. Bissonnette, 2015, The Journal of investigative dermatology.

Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib

J. Silverberg, V. Sikirica, J. Cappelleri, 2021, Dermatitis : contact, atopic, occupational, drug.

Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis

R. Bissonnette, R. Langley, V. Ho, 2009, Journal of cutaneous medicine and surgery.

Increase in coronary atherosclerosis severity and the prevalence of coronary artery mixed plaques in patients with psoriasis

J. Tardif, R. Bissonnette, F. Cademartiti, 2017, The British journal of dermatology.

Photodynamic therapy with toluidine blue in Jurkat cells: cytotoxicity, subcellular localization and apoptosis induction

F. Gad, R. Bissonnette, J. Tremblay, 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study

A. Kimball, K. Papp, K. Gordon, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: long‐term safety and efficacy in an open‐label extension study

H. Valdez, R. Bissonnette, F. Valenzuela, 2018, The British journal of dermatology.

Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis.

R. Schmid, S. Visvanathan, Patrick Baum, 2021, The Journal of allergy and clinical immunology.

Protoporphyrin IX fluorescence kinetics in UV-induced tumours and normal skin of hairless mice after topical application of 5-aminolevulinic acid methyl ester.

J. Moan, P. Juzenas, R. Bissonnette, 2002, Journal of photochemistry and photobiology. B, Biology.

Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis

A. Praestgaard, M. Boguniewicz, A. Zhang, 2022, Allergy.

Treatment of notalgia paresthetica with botulinum toxin A: a double-blind randomized controlled trial.

R. Bissonnette, C. Maari, P. Marchessault, 2014, Journal of the American Academy of Dermatology.

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

J. Thyssen, K. Papp, E. Simpson, 2022, JAMA dermatology.

Support Needed to Involve Psoriasis Patients in Treatment Decisions: Survey of Dermatologists

H. Lui, W. Gulliver, D. Stacey, 2011, Journal of cutaneous medicine and surgery.

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis.

K. Papp, R. Bissonnette, Y. Poulin, 2006, Journal of the American Academy of Dermatology.

A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis

R. Bissonnette, S. Yeleswaram, R. Call, 2022, American Journal of Clinical Dermatology.

Topical Agents for the Treatment of Psoriasis, Past, Present and Future

R. Bissonnette, J. Tremblay, 2002 .

Follow-up of Patients With Keratinocyte Carcinoma: A Systematic Review of Clinical Practice Guidelines.

A. Drucker, M. Gooderham, K. Papp, 2022, JAMA dermatology.

Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis.

L. Denis, Ning Zhang, R. Bissonnette, 2019, The Journal of allergy and clinical immunology.

Efficacy and Tolerability of Topical Tacrolimus Ointment for the Treatment of Male Genital Psoriasis

R. Bissonnette, S. Nigen, C. Bolduc, 2008, Journal of cutaneous medicine and surgery.

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies

S. Shumack, T. Biedermann, M. Richard, 2021, Acta dermato-venereologica.

Influence of the quantity of sunscreen applied on the ability to protect against ultraviolet‐induced polymorphous light eruption

R. Bissonnette, S. Nigen, C. Bolduc, 2012, Photodermatology, photoimmunology & photomedicine.

Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic AhR modulating agent (TAMA).

A. Armstrong, R. Bissonnette, L. Gold, 2020, Journal of the American Academy of Dermatology.

Update on sunscreens.

R. Bissonnette, 2008, Skin therapy letter.

Photodynamic therapy for skin field cancerization: an international consensus. International Society for Photodynamic Therapy in Dermatology

P Calzavara-Pinton, H. Wulf, A. Sidoroff, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Comparison of the ability of 2 sunscreens to protect against polymorphous light eruption induced by a UV-A/UV-B metal halide lamp.

H. Lui, D. Moyal, R. Bissonnette, 1999, Archives of dermatology.

Prevention of polymorphous light eruption and solar urticaria.

R. Bissonnette, 2002, Skin therapy letter.

Comparison of UVA protection afforded by high sun protection factor sunscreens.

D. Moyal, R. Bissonnette, N. Provost, 2000, Journal of the American Academy of Dermatology.

Treatment of Refractory Solar Urticaria with Plasma Exchange

H. Lui, D. McLean, H. Lui, 1999, Journal of cutaneous medicine and surgery.

Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison

B. Dréno, R. Bissonnette, Jerry Tan, 2018, American Journal of Clinical Dermatology.

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

W. Gulliver, J. Pope, B. Haraoui, 2015, Annals of the rheumatic diseases.

A double‐blind study of tolerance and efficacy of a new urea‐containing moisturizer in patients with atopic dermatitis

S. Seité, R. Bissonnette, S. Nigen, 2010, Journal of cosmetic dermatology.

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis

K. Papp, R. Bissonnette, Y. Poulin, 2010, The Journal of dermatological treatment.

Evidence Review of Topical Calcineurin Inhibitors for the Treatment of Adult Atopic Dermatitis

M. Gooderham, R. Bissonnette, C. Hong, 2019, Journal of cutaneous medicine and surgery.

Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.

K. Papp, R. Bissonnette, Y. Poulin, 2010, Cutis.

Restoration of hair growth with topical diphencyprone in mouse and rat models of alopecia areata.

J. Sundberg, J. Shapiro, D. McLean, 2003, Journal of the American Academy of Dermatology.

Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005.

Ann-Marie Wennberg, Peter Foley, Rik Roelandts, 2007, Journal of the American Academy of Dermatology.

Topical agents for the treatment of psoriasis, past, present and future.

R. Bissonnette, J. Tremblay, 2002, Journal of cutaneous medicine and surgery.

Canadian Hand Dermatitis Management Guidelines

T. Agner, W. Gulliver, R. Bissonnette, 2010, Journal of cutaneous medicine and surgery.

DRUG‐INDUCED TOXIC PUSTULODERMA

R. Bissonnette, G. Allaire, J. Tousignant, 1992, International journal of dermatology.

A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis

R. Bissonnette, A. Nasir, J. Dubois, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris

M. Suárez-Fariñas, R. Bissonnette, J. Krueger, 2016, PloS one.

Redefining treatment options in chronic hand eczema (CHE)

H. Maibach, P. Elsner, T. Luger, 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

Prolidase deficiency: a multisystemic hereditary disorder.

V. D. Der Kaloustian, R. Bissonnette, R. Dubuc, 1993, Journal of the American Academy of Dermatology.

Randomized trial comparing a chemical peel containing a lipophilic hydroxy acid derivative of salicylic acid with a salicylic acid peel in subjects with comedonal acne

S. Seité, R. Bissonnette, I. Hamzavi, 2011, Journal of cosmetic dermatology.

Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

S. Feldman, Z. Draelos, L. Iversen, 2016, BMC Dermatology.

Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept.

R. Bissonnette, Y. Poulin, L. Guenther, 2010, Journal of the American Academy of Dermatology.

Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris

S. Seité, R. Bissonnette, S. Nigen, 2009, Journal of cosmetic dermatology.

Multiple Large-Surface Photodynamic Therapy Sessions with Topical or Systemic Aminolevulinic Acid and Blue Light in UV-Exposed Hairless Mice

R. Bissonnette, Younan Liu, G. Viau, 2004, Journal of cutaneous medicine and surgery.

Repeated exposure to blue light does not improve psoriasis.

R. Bissonnette, C. Maari, G. Viau, 2003, Journal of the American Academy of Dermatology.

Oral Aminolevulinic Acid Induces Protoporphyrin IX Fluorescence in Psoriatic Plaques and Peripheral Blood Cells†,¶

D I McLean, M. Korbelik, D. McLean, 2001, Photochemistry and photobiology.

Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema

M. Worm, R. Bissonnette, L. Guenther, 2010, The British journal of dermatology.

Open-label exploratory study of acitretin for the treatment of severe chronic hand dermatitis

R. Bissonnette, Jerry Tan, S. Nigen, 2015, The Journal of dermatological treatment.

An open‐label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids

K. Reich, R. Bissonnette, T. Dirschka, 2011, Clinical and experimental dermatology.

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

K. Papp, R. Bissonnette, K. Papp, 2013, The British journal of dermatology.

Long-Term Effectiveness and Safety of Up to 48 Weeks’ Treatment with Topical Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in the Prevention and Reduction of Atrophic Acne Scars in Moderate and Severe Facial Acne

B. Dréno, R. Bissonnette, Jerry Tan, 2019, American Journal of Clinical Dermatology.

Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies

A. Bitton, Deepali Kumar, S. Jamal, 2018, Journal of cutaneous medicine and surgery.

The Next Phase of Real-World Clinical Experience with Alefacept: The AWARE-2 Registry

R. Bissonnette, N. Shear, G. Searles, 2009, Journal of cutaneous medicine and surgery.

Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition

M. Wiseman, M. Gooderham, K. Papp, 2017, Journal of cutaneous medicine and surgery.

Mo1884 Prevalence of Inflammatory Bowel Disease Among Patients With Psoriasis and Incidence of Serious Infections in This Subset: Results From the PSOLAR Registry

M. Augustin, E. Loftus, G. Krueger, 2016 .

Inflammatory Skin Disorders: Monocyte-Derived Cells Take Center Stage

E. Muñoz-Elías, R. Bissonnette, M. Sarfati, 2021, Frontiers in Immunology.

Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis

Martin M. Schumacher, F. Kolbinger, K. Papp, 2015, Experimental dermatology.

Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council

L. Iversen, R. Bissonnette, C. Lynde, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Socioeconomic Burden of Immune-Mediated Inflammatory Diseases — Focusing on Work Productivity and Disability

P. Jacobs, R. Bissonnette, L. Guenther, 2011, The Journal of Rheumatology. Supplement.

One-Year Safety and Efficacy of Tapinarof Cream for the Treatment of Plaque Psoriasis: Results from the PSOARING 3 Trial.

B. Strober, M. Lebwohl, S. Piscitelli, 2022, Journal of the American Academy of Dermatology.

Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.

B. Strober, M. Lebwohl, S. Piscitelli, 2021, The New England journal of medicine.

Phase 2, randomized dose‐finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis

J. Peppers, K. Robbins, J. Kraus, 2019, Journal of the American Academy of Dermatology.

Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study

T. Collingwood, R. Bissonnette, J. Bullman, 2018, Clinical pharmacology in drug development.

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

M. Gooderham, K. Papp, R. Bissonnette, 2016, The British journal of dermatology.

Chemoprevention of Skin Cancer with Photodynamic Therapy

R. Bissonnette, 2011 .

NOD2 Agonism Counter-Regulates Human Type 2 T Cell Functions in Peripheral Blood Mononuclear Cell Cultures: Implications for Atopic Dermatitis

J. Madrenas, C. Piccirillo, R. Bissonnette, 2023, Biomolecules.

Efficacy and safety of ixekizumab in a randomized, double‐blinded, placebo‐controlled phase IIIb study of patients with moderate‐to‐severe genital psoriasis

A. Gottlieb, R. Burge, A. Menter, 2018, The British journal of dermatology.

Short‐ and long‐term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

B. Strober, M. Lebwohl, L. Ferris, 2017, Journal of the American Academy of Dermatology.

The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital Psoriasis.

A. Gottlieb, A. Menter, K. Duffin, 2017, Journal of drugs in dermatology : JDD.

Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent.

R. Bissonnette, H. Teixeira, W. Valdecantos, 2016, Journal of the American Academy of Dermatology.

Practical Management of Patients with Atopic Dermatitis on Dupilumab

M. Gooderham, K. Papp, R. Bissonnette, 2021, Dermatology and Therapy.

Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis.

R. Bissonnette, M. Rubio, M. Sarfati, 2015, The Journal of allergy and clinical immunology.

Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis.

Ning Zhang, R. Bissonnette, J. Krueger, 2020, The Journal of allergy and clinical immunology.

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis

R. Bissonnette, N. Bhakta, S. Baumgartner, 2021, Dermatology and Therapy.

Measuring Atopic Dermatitis Disease Severity: The Potential for Electronic Tools to Benefit Clinical Care.

T. Bieber, R. Bissonnette, L. Maintz, 2021, The journal of allergy and clinical immunology. In practice.

Current status of photodynamic therapy in dermatology.

H Lui, H. Lui, R. Bissonnette, 1997, Dermatologic clinics.

Daylight photodynamic therapy for actinic keratosis: an international consensus

P Calzavara-Pinton, H. Wulf, A. Sidoroff, 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

Perforation of large and small bowel in Henoch‐Schonlein purpura

R. Bissonnette, J. Paradis, Alain Dansereau, 1997, International journal of dermatology.

Validity of Quality of Life Measurement Tools — From Generic to Disease-specific

C. Ware, G. Wells, B. Haraoui, 2011, The Journal of Rheumatology. Supplement.

Protection Afforded by Sunscreens Containing Inorganic Sunscreening Agents Against Blue Light Sensitivity Induced by Aminolevulinic Acid

R. Bissonnette, S. Nigen, T. Nocera, 2008, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis

R. Knight, J. Silverberg, T. Kosciólek, 2019, Journal of Investigative Dermatology.

Ultraviolet a Radiation and The Need for Protection

R. Bissonnette, Aditya K. Gupta, J. Claveau, 2006 .

Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial

R. Bissonnette, S. Nigen, C. Maari, 2014, The Journal of dermatological treatment.

Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative

W. Gulliver, J. Pope, B. Haraoui, 2015, The Journal of Rheumatology.

Effects of the TNF alpha Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients with Psoriasis : Results of a Randomized Controlled Trial

J. Pressacco, M. Guertin, R. Bissonnette, 2012 .

Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial

B. Dréno, R. Bissonnette, J. Tan, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Differential Changes in Inflammatory Mononuclear Phagocyte and T Cell Profiles within Psoriatic Skin during Treatment with Guselkumab versus Secukinumab.

E. Muñoz-Elías, K. Reich, A. Blauvelt, 2021, The Journal of investigative dermatology.

Short incubation photodynamic therapy with methylaminolevulinate and no occlusion for the treatment of actinic keratoses.

R. Bissonnette, S. Nigen, C. Maari, 2012, Journal of the American Academy of Dermatology.

Major differences in expression of inflammatory pathways in skin from different body sites of healthy individuals.

R. Bissonnette, J. Krueger, E. Guttman‐Yassky, 2019, The Journal of investigative dermatology.

Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes.

C. Elmets, D. McLean, H. Lui, 2004, Archives of dermatology.

Vascular inflammation in moderate‐to‐severe atopic dermatitis is associated with enhanced Th2 response

J. Tardif, Ning Zhang, R. Bissonnette, 2021, Allergy.

Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases

R. Bissonnette, J. Krueger, F. Ramírez-Valle, 2022, Allergy.

Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis

S. Feldman, W. Barry, Y. Helfrich, 2021, JAMA dermatology.

Safety and Efficacy of Adalimumab for the Treatment of Severe Alopecia Areata: Case Series of Three Patients

R. Bissonnette, C. Bolduc, 2012, Journal of cutaneous medicine and surgery.

Construction et validation de l'chelle de Satisfaction dans les tudes (ESDE).

R. Vallerand, R. Bissonnette, 1990 .

Treatment Decision Needs of Psoriasis Patients: Cross-sectional Survey

H. Lui, W. Gulliver, D. Stacey, 2010, Journal of cutaneous medicine and surgery.

Changes in serum free testosterone, sleep patterns, and 5‐alpha‐reductase type I activity influence changes in sebum excretion in female subjects

K. McElwee, R. Bissonnette, S. Nigen, 2015, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

J. Paolini, G. Yosipovitch, R. Bissonnette, 2023, EClinicalMedicine.

Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.

R. Bissonnette, C. Munera, Brian S. Kim, 2023, The New England journal of medicine.

Characterization of 57 kDa statin as a true marker for growth arrest in tissue by its disappearance from regenerating liver

E. Wang, R. Bissonnette, M. Sandig, 1994, Journal of cellular physiology.

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events

J. Silverberg, E. Simpson, K. Kabashima, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial

J. Silverberg, E. Peeva, G. Girolomoni, 2021, Dermatology and Therapy.

Tapinarof Cream 1% Once Daily for the Treatment of Moderate to Severe Atopic Dermatitis in Children and Adults: The Pivotal Phase 3 ADORING Clinical Program

J. Silverberg, S. Piscitelli, R. Bissonnette, 2021, SKIN The Journal of Cutaneous Medicine.

Folliculitis with tapinarof, when it occurs, is generally mild, self-limiting, and rarely interferes with therapy.

A. Armstrong, R. Bissonnette, L. Gold, 2021, Journal of the American Academy of Dermatology.

Efficacy of Tapinarof Cream by Body Region in Subjects With Plaque Psoriasis in a Phase 2b Randomized Controlled Study

A. Armstrong, R. Bissonnette, S. Tyring, 2020 .

Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.

M. Lebwohl, A. Pink, H. Valdez, 2022, Journal of Allergy and Clinical Immunology: In Practice.

Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

B. Strober, M. Lebwohl, A. Armstrong, 2020 .

Use of Lesion Response Rate in Actinic Keratosis Trials

R. Bissonnette, R. Szeimies, P. Atanasov, 2016, Dermatology and Therapy.

Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy

A. Armstrong, R. Bissonnette, L. Gold, 2021, Journal of the American Academy of Dermatology.

The preponderance of evidence supports an AhR-dependent mechanism of action of tapinarof.

A. Armstrong, R. Bissonnette, L. Gold, 2021, Journal of the American Academy of Dermatology.

The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof

R. Bissonnette, A. Tallman, D. Rubenstein, 2021 .

Photodynamic therapy with methylaminolevulinate 80 mg/g without occlusion improves acne vulgaris.

R. Bissonnette, S. Nigen, N. Provost, 2010, Journal of drugs in dermatology : JDD.

Systemic photodynamic therapy with aminolaevulinic acid delays the appearance of ultraviolet‐induced skin tumours in mice

H. Lui, R. Bissonnette, D. Bouffard, 2001, The British journal of dermatology.

Chronic Hand Eczema Guidelines From an Expert Panel of the International Eczema Council

J. Silverberg, T. Agner, J. Thyssen, 2020, Dermatitis : contact, atopic, occupational, drug.

Fatigue and Quality of Sleep in Patients with Immune-Mediated Inflammatory Disease

C. Bernstein, L. Graff, R. Bissonnette, 2011, The Journal of Rheumatology. Supplement.

102 Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Patients With Atopic Dermatitis

R. Knight, J. Silverberg, C. Callewaert, 2019, Journal of Investigative Dermatology.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document

M. Wiseman, M. Gooderham, K. Papp, 2018, Journal of Cutaneous Medicine and Surgery.

Photodynamic Therapy with 5-Aminolevulinic Acid Induces Apoptosis and Caspase Activation in Malignant T Cells

F. Gad, R. Bissonnette, R. Bertrand, 2001, Journal of cutaneous medicine and surgery.

The safety and efficacy of four different fixed combination regimens of adapalene 0.1%/benzoyl peroxide 2.5% gel for the treatment of acne vulgaris: results from a randomised controlled study

R. Bissonnette, Jerry Tan, N. Kerrouche, 2018, European Journal of Dermatology.

34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: Pooled analysis from two randomized phase 3 studies

E. Simpson, R. Bissonnette, L. Stein Gold, 2022, Journal of the American Academy of Dermatology.

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

L. Ferris, Z. Draelos, M. Gooderham, 2020, SKIN The Journal of Cutaneous Medicine.

Intrapatient comparison of atopic dermatitis skin transcriptome shows differences between tape‐strips and biopsies

Y. Liu, R. Bissonnette, J. Krueger, 2023, Allergy.

Efficacy and safety of etrasimod, a sphingosine 1‐phosphate receptor modulator, in adults with moderate‐to‐severe atopic dermatitis (ADVISE)

J. Silverberg, D. Murrell, R. Bissonnette, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIa study

T. Bieber, R. Bissonnette, W. Abramovits, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

Etanercept in the treatment of palmoplantar pustulosis.

R. Bissonnette, Y. Poulin, J. Syrotuik, 2008, Journal of drugs in dermatology : JDD.

International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale

J. Silverberg, A. Paller, K. Abuabara, 2020, BMJ Open.

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

R. Bissonnette, Y. Poulin, C. Lynde, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

R. Bissonnette, Y. Poulin, K. Papp, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Persistence of inflammatory phenotype in residual psoriatic plaques in patients on effective biologic therapy: Residual Psoriatic Plaques After Treatment.

Kathleen M. Smith, V. Kaimal, R. Bissonnette, 2019, The Journal of investigative dermatology.

Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab

R. Bissonnette, R. Vender, C. Maari, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Letter: Photodynamic Therapy with Methyl Aminolevulinate Induces Phototoxic Reactions on Areas of the Nose Adjacent to Basal Cell Carcinomas and Actinic Keratoses

R. Bissonnette, 2008 .

Prospective Study of Pathogenesis of Atrophic Acne Scars and Role of Macular Erythema.

P. Reynier, B. Dréno, R. Bissonnette, 2017, Journal of Drugs in Dermatology.

Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.

J. Silverberg, E. Simpson, K. Reich, 2022, The British journal of dermatology.

Oral prednisone regulates human skin T cells in delayed‐type hypersensitivity reaction elicited by diphencyprone

R. Bissonnette, F. Ramírez-Valle, M. Sarfati, 2023, Allergy.

B. Strober, M. Lebwohl, L. Naldi, 2016 .

Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials

R. Bissonnette, C. Maari, E. Saint-Cyr Proulx, 2023, Journal of clinical medicine.

560 KPL-716, anti-Oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis

J. Paolini, R. Bissonnette, S. Tyring, 2019, Journal of Investigative Dermatology.

W. Gulliver, B. Haraoui, C. Roubille, 2015, The Journal of Rheumatology.

THU0412 Cardiovascular Outcomes in Patients with Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analyses

W. Gulliver, J. Pope, B. Haraoui, 2014 .

Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

W. Gulliver, M. Gooderham, K. Papp, 2023, Journal of cutaneous medicine and surgery.

The AWARE Study: Methodology and Baseline Characteristics

H. Lui, W. Gulliver, K. Papp, 2009, Journal of Cutaneous Medicine and Surgery.

Patterns of Combination Therapy with Alefacept for the Treatment of Psoriasis in Canada in the AWARE Study

H. Lui, K. Papp, R. Bissonnette, 2009, Journal of cutaneous medicine and surgery.

Dupilumab treatment significantly improves skin barrier function in adult and adolescent patients with moderate to severe atopic dermatitis

M. Boguniewicz, A. Zhang, R. Bissonnette, 2022, Journal of Allergy and Clinical Immunology.

Dupilumab inhibits vascular leakage of blood proteins into atopic dermatitis skin.

M. Boguniewicz, A. Zhang, R. Bissonnette, 2023, Journal of Allergy and Clinical Immunology: In Practice.

Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

I. Hussain, M. Ardeleanu, S. Forman, 2017 .

Fatal carcinoid crisis after percutaneous fine-needle biopsy of hepatic metastasis: case report and literature review.

R. Bissonnette, A. Buckley, R. Gibney, 1990, Radiology.

Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin.

J. Werth, R. Bissonnette, C. Zang, 2023, Journal of the American Academy of Dermatology.

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement

J. Silverberg, R. Bissonnette, E. Guttman‐Yassky, 2019 .

Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials

E. Simpson, A. Wollenberg, R. Bissonnette, 2022, European Journal of Dermatology.

The Treat-to-Target Project in Atopic Dermatitis: One Year On

S. Shumack, T. Biedermann, J. Thyssen, 2023, Acta dermato-venereologica.

Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section V: Consensus Statements on the Assessment and Management of Adult Patients With Moderate-to-Severe Atopic Dermatitis

M. Wiseman, M. Gooderham, K. Papp, 2018, Journal of cutaneous medicine and surgery.

Validity of Quality of Life Measurement Tools — From Generic to Disease-specific

C. Ware, G. Wells, B. Haraoui, 2011, The Journal of Rheumatology. Supplement.

Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition

M. Wiseman, M. Gooderham, K. Papp, 2017, Journal of cutaneous medicine and surgery.

TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study.

J. Tardif, M. Guertin, R. Bissonnette, 2017, The Journal of investigative dermatology.

Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study.

R. Bissonnette, J. Correa da Rosa, E. Guttman‐Yassky, 2023, Allergy.

Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study.

Yusong Chen, J. Fowler, R. Bissonnette, 2023, Journal of the American Academy of Dermatology.

M. Lahfa, T. Ruzicka, R. Bissonnette, 2008, The British journal of dermatology.

K. Papp, R. Bissonnette, R. Langley, 2010, International journal of dermatology.

Treat‐to‐target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis

J. Silverberg, A. Paller, A. Drucker, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Sensitivity of clinician‐assessed efficacy outcome measurement instruments in trials of topical therapies for atopic dermatitis: a systematic review and meta‐analysis

R. Bissonnette, M. Chagnon, K. Kojok, 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

JAK inhibitors appear to have a bright future in the treatment of atopic dermatitis

R. Bissonnette, 2018, The British journal of dermatology.